Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Frank Leebeek & Greta Mulder of Erasmus MC, Lutz Bonacker of CSL Behring Share Insight on Etranacogene Dezaparvovec for the Treatment of Hemophilia B
VIEWPOINTS

PharmaShots Interview: Frank Leebeek & Greta Mulder of Erasmus MC, Lutz Bonacker of CSL Behring Share Insight on Etranacogene Dezaparvovec for the Treatment of Hemophilia B

In an interview with PharmaShots, Frank Leebeek, MD, Ph.D., Hematology Department Head & Greta Mulders, Nurse Practitioner, Study Coordinator at the Erasmus Medical Center in Rotterdam, Lutz Bonacker, Senior Vice President, General Manager, Commercial Operations Europe at CSL Behring shared their views on the data of Etranacogene Dezaparvovec in P-III (HOPE-B) trial for the treatment of Hemophilia B, presented at EAHAD 2022…
April 4, 2022

Read more

PharmaShots Interview Eli Lilly’s Eric Pearlman Shares Insight on Emgality (galcanezumab-gnlm) for the Treatment of Episodic Migraine
VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Eric Pearlman Shares Insight on Emgality (galcanezumab-gnlm) for the Treatment of Episodic Migraine

In an interview with PharmaShots, Eric Pearlman, Associate Vice President, Global & US Medical Affairs at Eli Lilly shared his views on the initiation of the patients enrollment in P-IV (CHALLENGE-MIG) head-to-head trial of Emgality for episodic migraine in adultsShots:The company initiate the patients' enrollment for the P-IV (CHALLENGE-MIG) head-to-head trial to evaluate the efficacy and safety of Emgality vs Nurtec ODT…
March 29, 2022

Read more

PharmaShots Interview Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof
VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

In an interview with PharmaShots, Philip Brown, Chief Medical Officer at Dermavant share his views on the data of Tapinarof in the P-III (PSOARING 3) study for the treatment of Plaque Psoriasis & highlights new patient satisfaction dataShots:The P-III (PSOARING 3) extension study evaluates tapinarof (1%, qd) in adult patients with PsO for ~40wks. & a 4wks. safety follow-up periodThe…
March 15, 2022

Read more

PharmaShots Interview Jazz Pharmaceuticals’ Bruce C. Cozadd Shares Insight on Vision 2025 During the Virtual Presentation at 40th Annual J.P. Morgan Healthcare Conference 2022
VIEWPOINTS

PharmaShots Interview: Jazz Pharmaceuticals’ Bruce C. Cozadd Shares Insight on Vision 2025 During the Virtual Presentation at 40th Annual J.P. Morgan Healthcare Conference 2022

In an interview with PharmaShots, Bruce C. Cozadd, Chairman and Chief Executive Officer at Jazz Pharmaceuticals shared his views on Vision 2025 to deliver sustainable growth and enhanced valueShots:The company reported Vision 2025 to deliver sustainable growth and enhanced value to drive the transformation to an innovative, high-growth, global biopharmaceutical leaderThe company is expected to…
March 14, 2022

Read more

PharmaShots Interview Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer
VIEWPOINTS

PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer

In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the enrolment of the final patient in the (ECLIPSE) trial for SHIELD blood test to treat Colorectal CancerShots:The company has reported the patient enrolment in the (ECLIPSE) trial to evaluate SHIELD blood test in 12750 patients aged 45-84yr. with colorectal…
March 9, 2022

Read more

PharmaShots Interview SalioGen Therapeutics’ Ray Tabibiazar Shares Insights on Gene Coding Platform
VIEWPOINTS

PharmaShots Interview: SalioGen Therapeutics’ Ray Tabibiazar Shares Insights on Gene Coding Platform

In an interview with PharmaShots, Ray Tabibiazar, M.D., Chief Executive Officer and Chairman, Board of Directors at SalioGen Therapeutics shares his views on the completion of $115M series B financing to advance gene coding platform for genetic diseasesShots:The company has completed $115M series B financing which was co-led by GordonMD global investments and EPIQ capital group. The financing will…
March 8, 2022

Read more

VIEWPOINTS

PharmaShots Interview: Clario’s Joyce Suhy Shares Insights on PET Imaging Clinical Trials

In an interview with PharmaShots, Joyce Suhy, Senior Vice President, Medical Imaging at Clario shares her views on the PET imaging clinical trials & expands its 2018 collaboration with XingImaging for Alzheimer’s disease and other neurodegenerative diseasesShots:Clario & XingImaging have expanded the collaboration to provide PET imaging clinical trials for neurodegenerative therapeutics in China. The initial study used Amyvid (florbetapir) PET imaging to…
March 1, 2022

Read more

Viewpoints_Senior Editor
VIEWPOINTS

PharmaShots Interview: Boston Scientific’s Ron Morton Shares Insights on the Rezūm Water Vapor Therapy

In an interview with PharmaShots, Ron Morton, Chief Medical Officer, Vice President of Medical Affairs, UroPH at Boston Scientific shares his views on Rezūm Water Vapor Therapy to reduces the size of the prostate and provides lasting symptom relief from benign prostatic hyperplasiaShots:The company reported the new data from a survey of 2,000 American men aged ≥60 conducted by…
February 24, 2022

Read more

Viewpoints_Tania Small
VIEWPOINTS

PharmaShots Interview: GSK’s Tania Small Shares Insight on Target the Future Program

In an interview with PharmaShots, Tania Small, Vice President of Global Medical Oncology at GSK shares her views on the launch of Target the Future Program to help address the challenges affecting the multiple myeloma communityShots:The company has launched Target the Future program to educate people in the field of multiple myeloma and address unmet needs in the communityA grant of…
February 23, 2022

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]